Active Ingredient History

  • Now
6-Aminocaproic acid (epsilon-aminocaproic acid, marketed as Amicar) is an ant fibrinolytic agent that acts by inhibiting plasminogen activators, which have fibrinolytic properties. It is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as a megakaryocytic thrombocytopenia (accompanying aplastic anemia); hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Aminocaproic acid binds reversibly to the kringle domain of plasminogen and blocks the binding of plasminogen to fibrin and its activation to plasmin. With NO activation of plasmin, there is a reduction in fibrinolysis. The drug should NOT be administered without a definite diagnosis and/or laboratory finding indicative of hyperfibrinolysis (hyperplasminemia). Inhibition of fibrinolysis by aminocaproic acid may theoretically result in clotting or thrombosis. However, there is no definite evidence that administration of aminocaproic acid has been responsible for the few reported cases of intravascular clotting which followed this treatment. Rather, it appears that such intravascular clotting was most likely due to the patient's preexisting clinical condition, e.g., the presence of DIC. It has been postulated that extravascular clots formed in vivo may not undergo spontaneous lysis as do normal clots. Reports have appeared in the literature of an increased incidence of certain neurological deficits such as hydrocephalus, cerebral ischemia, or cerebral vasospasm associated with the use of ant fibrinolytic agents in the treatment of subarachnoid hemorrhage (SAH). All of these events have also been described as part of the natural course of SAH, or as a consequence of diagnostic procedures such as angiography. Drug relatedness remains unclear. Aminocaproic acid may change the conformation of apoliprotein, changing its binding properties and potentially preventing the formation of lipoprotein.   NCATS

  • Mol. Mass: 131.1729
  • ALogP: 0.59
  • ChEMBL Molecule:
More Chemistry

Drug Pricing (per unit)

United States

$1.6430 - $30.2433
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

177 j.d | 177 j.d. | 6-aminocaproic acid | 6-aminohexanoic acid | acepramin | acide aminocaproïque | acide aminocaproque | ácido aminocapróico | acidum aminocaproicum | ahx | amicar | aminocaproic | aminocaproic acid | aminocapronsäure | aminohexanoic acid | caproamin | cl-10304 | cy-116 | eaca | epsicaprom | epsikapron | epsilcapramine | epsilon-ahx | epsilon aminocaproic acid | epsilon-aminocaproic acid | epsilon-aminohexanoic acid | z | ε-aminocaproic acid


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue